Research programme: sialidase inhibitors - OncoImmune
Latest Information Update: 30 Aug 2023
At a glance
- Originator OncoImmune
- Class Small molecules
- Mechanism of Action Neuraminidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Sepsis
Most Recent Events
- 30 Aug 2023 Discontinued - Preclinical for Sepsis (Prevention) in USA (unspecified route)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Sepsis(Prevention) in USA
- 22 Feb 2016 Preclinical trials in Sepsis (Prevention) in USA (unspecified route)